A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.
Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Obesity, particularly the severe class, was associated with an increased risk of mechanical ventilation and death in patients hospitalized with COVID-19 — a risk that is even more profound among the younger age group, reveals data from the AHA COVID-19 CVD registry*.
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Adding ticagrelor to aspirin significantly reduces the risk of stroke and death compared with aspirin alone in patients with plaque build-up in their arteries known as ipsilateral atherosclerotic stenosis — thus highlighting the patient subgroup most likely to benefit from the combination therapy, based on a prespecified analysis of the THALES* study.
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.